21
Participants
Start Date
November 20, 2018
Primary Completion Date
May 26, 2021
Study Completion Date
May 26, 2021
CPX-351
CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
CPX-351
CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
Weill Cornell Medical College, New York
New York Medical/Westchester, Valhalla
Georgetown University Medical Center, Washington D.C.
Wake Forest Baptist Health, Winston-Salem
Northside Hospital - Blood and Bone Marrow Transplant Group of Georgia, Atlanta
Medical College of Wisconsin, Milwaukee
University of Kansas Cancer Center, Westwood
Baylor University Medical Center, Dallas
Oregon Health and Science University, Portland
Fred Hutchinson Cancer Research Center, Seattle
Hackensack University Medical Center, Hackensack
Vancouver General Hospital, Vancouver
University Health Network/Princess Margaret Cancer Center, Toronto
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY